Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Now I believe they are a legit company
Hepion Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell on February 10, 2023
https://finance.yahoo.com/news/hepion-pharmaceuticals-ring-nasdaq-stock-211500723.html
Come on company give us a damn update on some of the current trials. We know your sitting on this info. Your buddy Makin is saying the Nash space is where it’s at. Prove him right!
Believe they had around 44 mil in cash at the end of last Q. Just look at the last release.
Do you know their cash situation? Any change that they will do offering soon?
Updated slide deck on their website btw.
Stick to landscaping and harass another board.
are you referring to the Brookline analysts report out ? I'll assume yes
Alliance Global Partners launched coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with a “buy” rating and price target of $4. Shares of Hepion closed at 73 cents on Jan. 31.
Analyst James Molloy writes that his recommendation is based primarily on expectations for Hepion’s rencofilstat, a cyclophilin inhibitor that is being developed to treat non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC) associated with NASH.
Please post link otherwise it's fake
Upwards and onwards my friend.. New buy rating out today with a 4 PT.
Nope. You are correct
Can't even day trade this dog chit
Keep your day job.
I'm a landscaper so I cant watch the ticker all day long for momentum stocks
And I don't pay for subscription services who probably are wrong half the time
So I cant answer your question
When hell freezes over. I’d love to know how we can find a 1000% mover.
$HEPA: Making major dough on $MSGM today..............
Will come back to $HEPA later.
Find the winners and let $HEPA do its thing
GO $HEPA
Is this dog chit ever going to move up ?
Did you own CABA btw? Just asking for a friend.
Trust me I didn’t pay 5. My average cost is 1.00. Like I said before I will sit and wait and see what happens. Hopefully it is a fun ride. In the meantime I will just continue to comment when I feel it is necessary. Have a great weekend.
$HEPA: Let me teach you how to make money.............
Do you see where $CABA was back in September 2022 ??
Just 5mos ago.
Now look at it.......... Can you see the yield ????
Can you see where we are on HEPA and where we are going ??
Yes ?????
If you bought HEPA at $5 whos problem is that ?? Mine ???
I'm not responsible for your irresponsible entries.
You can think whatever you want......... but if u don't know when to Enter and Exit a trade,
then it means that you know nothing at all.
WRT to opinions......... you know what they say about them right ???
Try and come back and let us know why you got into HEPA in the first place.
If u don't like it... move on, go elsewhere......... show us another company that can make u some money. No need to get emotionally wound up
GO $HEPA
I think everyone you re appear your selling some shares. As soon as you said something we’ve been on a downward spiral. Jmo
The main difference is the share structure between the two. This one is bloated with around 75 million and the other on is roughly around 15 million or so. That was the last time I looked.
Ready and willing to be blown away. Time will time.
$HEPA: If we're even 1/10 of MDGL..........
I'm happy.
Peer Competitor....... same space.......... we have lotssssssssss of gapfill to make up for.
Haven't even scratched the surface yet.
Get ready to get blown away.......... you'll remember me then.
GO $HEPA
I’ll be happy when they let this go and release the news they have been sitting on. Data is in hand just waiting for it to be released. Mgmt is iffy at best. Have my tickets and waiting for the real ride to start. Won’t be happy until it is way over my costs. Enough info for you.
$HEPA: Tapped $0.92.... you happy
The general trend is still higher.
More NASH relevant news to come for HEPA.... partyy is FAR from over
Try not to PANIC too much... theres no need to
GO $HEPA
$HEPA: Of course I’m here…..
Are you here because of me ?
I already pleaded my rationale ad nauseum… what more do you want me to say ?
The market will bring this to its right valuation or when deeper pockets realizes how under appreciated it is but unless there’s something more meaningful to say, we let this take its course.
NASH is the hot space …. HEPA is in the thick of it.
GO $HEPA
Sooooooooo confused here. You still with us or have yooooooooou moved on to greener pastures.
My condolences
I took advantage of the drop any picked up a few cheapies !!
I took advantage of the drop any picked up a few cheapies !!
Biotech investing is certainly not for the faint hearted. There is no reason for the sudden drop, other than it went up very quickly. There has been no bad news, in fact news has been pretty good. Cash on hand is at or near market cap and it looks like we have a very good liver drug.
The drop sucks as we got so close to going and staying above $1, but some have just been given the chance to buy at a 50% reduction, I know I doubled my holding.
Not going anywhere. I’m not a trader. Just don’t like to see such blatant manipulation. I still don’t trust the sleezy management, but I’m allowed to vent a little.
$HEPA: You sound soooooooooooo Confused
What happened ???
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170966059
GO $HEPA
I'm with you on this stock bud
Back to the crapper. Looks like an orchestrated rise and now the rug is being pulled out. Pure manipulation. Will this company stop screwing retail ever?
$HEPA: Don't worry.... healthy lil pullback
Dip buyers are gonna take advantage knowing that $MDGL still holding over 300 in the
NASH space.
Right now, HEPA gives more upside value here than does MDGL.
But the NASH space gets hotter and hotter, HEPA isn't done yet
GO $HEPA
There was really no need for this PR today. It killed the rally for the moment. When need some trial updates instead to continue this upward.
$HEPA: More Good NEWS....Rencofiilstat anticancer results from Myeloma
Nice results coming out again.
This isn't done yet............. NASH is HOT
GO $HEPA
Not a warrant player. But will hold tight. A bunch of updates should be on our way.
$HEPA: Thank u thank u..... thannkkkkkkkkkk you
Nice to get the props
Have you seen $HEPAs warrants............... lagggggggingggg, thats all I can say.
The were at $0.30 last year at this share price
GO $HEPA
Things look good. A nice PR AH would help the cause. Good call.
WOOOOOOOOW 100K SHARE BUY @1.09 AND 49K BUY @.96
y is this stock soooo hot??? cure 4 cancer???
$HEPA: Look at all the people showing up now..............
Wonder where they were when I was calling this..........
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170756736
And now they show up thinking like they know more. Funny STUFF.
THIS is NASH.......... look at $MDGL and where it is, there is your CLUE
Hepion warrants are dirt cheap....... still haven't caught up to commons
GO $HEPA
I like seeing us up, but there’s no real volume , just a few longs buying.
Was looking for a big dip today and it kept going. Very surprised, RSI now at 88
maybe Tuesday
Followers
|
83
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2139
|
Created
|
12/18/14
|
Type
|
Free
|
Moderators |
Hepion Pharmaceuticals (Nasdaq: $HEPA) is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection (HBV, HCV, HDV).
Hepion announced top line data from the low dose cohort in the Company's Phase 2a ‘AMBITION' clinical trial of CRV431, an oral, once daily novel cyclophilin inhibitor. This Phase 2a study is continuing with the higher dose of 225 mg CRV431, with NASH patient dosing expected to be completed in Q1-2021.In 2021, of the more than 300 million people living with HBV infection, 10.5% (27 million) were aware of their infection. Non-alcoholic Fatty Liver Disease (NAFLD) affects up to 25% of people in the United States. There are currently no medicines that can cure non-alcoholic Fatty Liver Disease effectively. The same can be said with HBV. With the momentum growing around hepatitis B drug discovery research, we are closer than ever to a cure.
Fact: The inflows have been massive the last 2 weeks. Reason why In just 28 days at the low dose, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish.
Bottom line The FDA looks for safety first we have the safest NASH drug our efficacy data is better than MDGL & AKRO. there market caps our almost 10x HEPA. Smart savvy biotech investors with deep pockets know this and are accumulating all they can of HEPA at these levels.
One morning we can wake up and see the price has tripled from its 160 market cap. Also they have 120 million in cash burning under 5 million a quarter. Lots of moving parts here. Gilead & Novo in the mix we will see? A new molecule being added to the pipeline. This management team is experienced 100 years total and world renown experts on cyclophilin inhibitors. They brought a FDA approved blockbuster drug to market already.
June 2021 Hepa Biz Presentation
https://hepionpharma.com/wp-content/uploads/2021/06/Corporate-deck-June-2021-FINAL.pdf
HEPA AI-POWR
https://hepionpharma.com/ai-powr/
HEPA Tackling Chronic Liver Disease - CRV431 Mechanism of Action
https://www.youtube.com/watch?v=CE7es4l1avM
HEPA GLOBAL NASH CONFERENCE PRESENTATION:
https://12ewye24eigk3g5kwa2dxjzm-wpengine.netdna-ssl.com/wp-content/uploads/2021/04/4thGlobal_NASH_Congress_Draft_20Apr2021_FINAL-1.pdf
HEPA website
https://hepionpharma.com
Chairman of the Board, Gary Jacob, is not just a business guy, he's one hell of a biochemist, and you can bet he has a solid grasp of everything that's going on with Hepion.
He's a key player here!
His background goes way beyond what you ordinarily see on the BOD of little R&D biotechs. You might see those with his research background on Scientific Advisory Boards, but they wouldn't have a fraction of the business expertise he's got.
Hepion has the whole package, with this guy!!
Hepion Pharmaceuticals Welcomes Dr. Stephen Harrison to its Scientific Advisory Board
https://www.globenewswire.com/news-release/2019/08/07/1898563/0/en/Hepion-Pharmaceuticals-Welcomes-Dr-Stephen-Harrison-to-its-Scientific-Advisory-Board.html
Former Novo Nordisk Executive, Dr. Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer
Todd Hobbs coming to Hepion. It was published in December. Hobbs' primary focus has always been on diabetes, and I have said many times that there's a blockbuster reason for him leaving his position as Vice President, Chief Medical Officer at Novo Nordisk, a USD 190B global pharmaceutical behemoth, after nearly 17 years there, to come to tiny Hepion.
I believe we'll be hearing about CRV431 in the treatment of diabetes, as it has the highest known potency of any reported cyclophilin inhibitor known, by a wide margin...
https://www.biospace.com/article/releases/former-novo-nordisk-executive-dr-todd-m-hobbs-joins-hepion-pharmaceuticals-as-chief-medical-officer/
Nash Phase 2 & 3 Trials by companies in the space:
AKRO Akero Therapeutics 1.1 Billion Marketcap 240 Million in cash
MDGL Madrigal Pharmaceutical 1.7 Billion Marketcap 300 Million in cash
HEPA Hepion Pharmaceuticals 160 Million market cap 120 million in cash
Currently trading at $2.2 due to a public offering of 44.000.000 shares $2
According to analysts' consensus price target of $80.00, Hepion Pharmaceuticals has a forecasted upside of 3,503.6% from its current price of $2.22.
$HEPA
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |